Portfolio Holdings Detail for ISIN IE00BDZVHG35
Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /var/www/liquidata/show_ticker_holding_ETFs.php on line 67
Stock Name / Fund iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer Blackrock

ETF Ticker BTEE(USD) LSE
ETF Ticker BTEE.L(GBP) LSE

Holdings detail for NBIX

Stock Name	Neurocrine Biosciences Inc
Ticker	NBIX(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US64125C1099
LEI	549300FECER0XBN49756

Show aggregate NBIX holdings

News associated with NBIX

Sum Up The Parts: SCHG Could Be Worth $34: Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-08-21 10:23:31
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Maryland State Retirement & Pension System: Maryland State Retirement & Pension System lowered its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 12.5% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,661 shares of the company’s stock after selling 663 shares during the quarter. Maryland […] - 2025-08-15 05:24:56
Charles Schwab Investment Management Inc. Purchases 13,216 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX): Charles Schwab Investment Management Inc. raised its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 1.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 775,773 shares of the company’s stock after acquiring an additional 13,216 shares during the quarter. Charles […] - 2025-08-13 05:10:46
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Blair William & Co. IL: Blair William & Co. IL cut its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 3.7% in the first quarter, Holdings Channel reports. The fund owned 6,214 shares of the company’s stock after selling 242 shares during the period. Blair William & Co. IL’s holdings in Neurocrine Biosciences were worth $687,000 at the […] - 2025-08-11 05:52:52
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Federated Hermes Inc.: Federated Hermes Inc. trimmed its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 72.9% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 9,441 shares of the company’s stock after selling 25,402 shares during the quarter. Federated Hermes Inc.’s […] - 2025-08-07 05:22:58
Natixis Advisors LLC Sells 292 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX): Natixis Advisors LLC lowered its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 0.9% in the first quarter, Holdings Channel.com reports. The institutional investor owned 33,312 shares of the company’s stock after selling 292 shares during the period. Natixis Advisors LLC’s holdings in Neurocrine Biosciences were worth $3,684,000 at the end of the […] - 2025-08-07 04:49:07
Neurocrine (NBIX) Q2 2025 Earnings Call Transcript: @media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo - 2025-08-05 01:16:10
Neurocrine (NBIX) Q2 Revenue Jumps 17%: Key PointsNon-GAAP earnings per share of $1.65 for Q2 2025 vastly exceeded the analyst estimate of $0.96. - 2025-08-01 01:15:16
13,202 Shares in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Bought by Y Intercept Hong Kong Ltd: Y Intercept Hong Kong Ltd acquired a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) in the 1st quarter, HoldingsChannel.com reports. The fund acquired 13,202 shares of the company’s stock, valued at approximately $1,460,000. Other hedge funds and other institutional investors have also recently bought and sold shares of the company. […] - 2025-07-24 06:50:57
HighPoint Advisor Group LLC Purchases 366 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX): HighPoint Advisor Group LLC boosted its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 15.0% during the first quarter, Holdings Channel.com reports. The fund owned 2,812 shares of the company’s stock after acquiring an additional 366 shares during the quarter. HighPoint Advisor Group LLC’s holdings in Neurocrine Biosciences were worth $302,000 […] - 2025-07-24 05:51:14
Neurocrine Biosciences (NASDAQ:NBIX) Now Covered by Analysts at Truist Financial: Truist Financial initiated coverage on shares of Neurocrine Biosciences (NASDAQ:NBIX – Free Report) in a research report report published on Monday, Marketbeat reports. The firm issued a buy rating and a $163.00 price target on the stock. NBIX has been the subject of several other reports. Royal Bank Of Canada reaffirmed an “outperform” rating and […] - 2025-07-22 04:28:48
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Position Trimmed by Cerity Partners LLC: Cerity Partners LLC decreased its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 20.1% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 33,361 shares of the company’s stock after selling 8,376 shares during the quarter. Cerity Partners LLC’s holdings in […] - 2025-07-18 04:55:08
Ingrid Delaet Sells 457 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock: Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) insider Ingrid Delaet sold 457 shares of the business’s stock in a transaction on Thursday, July 10th. The stock was sold at an average price of $135.00, for a total transaction of $61,695.00. Following the completion of the transaction, the insider directly owned 4,730 shares in the […] - 2025-07-14 07:16:47
Bank of New York Mellon Corp Has $91.65 Million Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX): Bank of New York Mellon Corp lessened its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 4.8% during the first quarter, HoldingsChannel reports. The fund owned 828,682 shares of the company’s stock after selling 41,608 shares during the quarter. Bank of New York Mellon Corp’s holdings in Neurocrine Biosciences were worth $91,652,000 as […] - 2025-07-11 05:40:57
Principal Financial Group Inc. Has $27.48 Million Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX): Principal Financial Group Inc. reduced its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 1.6% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 248,420 shares of the company’s stock after selling 4,049 shares during the period. Principal Financial Group Inc. owned 0.25% of Neurocrine Biosciences […] - 2025-07-09 05:51:40
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Given Average Recommendation of “Moderate Buy” by Analysts: Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the twenty-two brokerages that are presently covering the stock, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and nineteen have given a buy recommendation to the company. The average 12 […] - 2025-07-09 03:09:50
First Horizon Advisors Inc. Has $43,000 Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX): First Horizon Advisors Inc. decreased its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 55.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 385 shares of the company’s stock after selling 480 shares during the quarter. First Horizon Advisors […] - 2025-07-08 05:49:06
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Jude Onyia Sells 20,362 Shares: Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) insider Jude Onyia sold 20,362 shares of the company’s stock in a transaction on Wednesday, July 2nd. The stock was sold at an average price of $130.13, for a total value of $2,649,707.06. Following the completion of the sale, the insider owned 18,289 shares of the company’s […] - 2025-07-08 05:06:50
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by KBC Group NV: KBC Group NV lessened its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 3.5% in the 1st quarter, Holdings Channel reports. The fund owned 13,835 shares of the company’s stock after selling 495 shares during the period. KBC Group NV’s holdings in Neurocrine Biosciences were worth $1,530,000 as of its most recent filing […] - 2025-07-04 06:58:45
New York State Teachers Retirement System Lowers Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX): New York State Teachers Retirement System lowered its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 1.9% during the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 108,481 shares of the company’s stock after selling 2,055 shares during the quarter. New York State Teachers Retirement System’s holdings in Neurocrine Biosciences were worth $11,998,000 […] - 2025-07-04 06:14:58
Amalgamated Bank Has $5.28 Million Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX): Amalgamated Bank lessened its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 3.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 47,719 shares of the company’s stock after selling 1,895 shares during the quarter. Amalgamated Bank’s holdings in Neurocrine Biosciences were […] - 2025-07-03 06:14:49
Sumitomo Mitsui Trust Group Inc. Sells 1,399 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX): Sumitomo Mitsui Trust Group Inc. reduced its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 0.6% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 231,458 shares of the company’s stock after selling 1,399 shares during the quarter. Sumitomo Mitsui Trust […] - 2025-07-03 05:35:01
Golden State Wealth Management LLC Grows Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX): Golden State Wealth Management LLC increased its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 116.9% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 397 shares of the company’s stock after purchasing an additional 214 shares during the quarter. […] - 2025-07-02 05:01:01
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Acquired by Oppenheimer & Co. Inc.: Oppenheimer & Co. Inc. raised its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 2.4% in the 1st quarter, HoldingsChannel.com reports. The fund owned 19,388 shares of the company’s stock after buying an additional 447 shares during the quarter. Oppenheimer & Co. Inc.’s holdings in Neurocrine Biosciences were worth $2,144,000 as […] - 2025-06-27 05:10:49
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Retirement Systems of Alabama: Retirement Systems of Alabama cut its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 1.4% in the 1st quarter, Holdings Channel reports. The firm owned 121,352 shares of the company’s stock after selling 1,755 shares during the period. Retirement Systems of Alabama’s holdings in Neurocrine Biosciences were worth $13,422,000 at the […] - 2025-06-23 05:04:51
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Bought by QRG Capital Management Inc.: QRG Capital Management Inc. lifted its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 7.1% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 20,062 shares of the company’s stock after buying an additional 1,330 shares […] - 2025-06-20 06:54:59
Sowell Financial Services LLC Takes Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX): Sowell Financial Services LLC bought a new stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 4,786 shares of the company’s stock, valued at approximately $529,000. Other institutional investors and hedge funds […] - 2025-06-20 05:29:06
Trust Point Inc. Sells 660 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX): Trust Point Inc. decreased its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 26.6% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,823 shares of the company’s stock after selling 660 shares during the period. Trust Point Inc.’s holdings in […] - 2025-06-19 05:35:02
XBI, EXAS, NBIX, NTRA: ETF Outflow Alert: Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $443.9 million dollar outflow -- that's a 8.8% decrease week over week - 2025-06-17 11:54:37
Merit Financial Group LLC Acquires 345 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX): Merit Financial Group LLC raised its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 9.1% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,153 shares of the company’s stock after purchasing an additional 345 shares during the quarter. Merit Financial Group […] - 2025-06-11 05:00:51

iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) NBIX holdings

Date	Number of NBIX Shares Held	Base Market Value of NBIX Shares	Local Market Value of NBIX Shares	Change in NBIX Shares Held	Change in NBIX Base Value	Current Price per NBIX Share Held	Previous Price per NBIX Share Held
2025-12-03 (Wednesday)	69,662	USD 10,585,838	USD 10,585,838	0	USD -36,224	USD 151.96	USD 152.48
2025-12-02 (Tuesday)	69,662	USD 10,622,062	USD 10,622,062	2,475	USD 484,887	USD 152.48	USD 150.88
2025-12-01 (Monday)	67,187	USD 10,137,175	USD 10,137,175	0	USD -85,999	USD 150.88	USD 152.16
2025-11-28 (Friday)	67,187	USD 10,223,174	USD 10,223,174	165	USD 63,979	USD 152.16	USD 151.58
2025-11-27 (Thursday)	67,022	USD 10,159,195	USD 10,159,195	0	USD 0	USD 151.58	USD 151.58
2025-11-26 (Wednesday)	67,022	USD 10,159,195	USD 10,159,195	495	USD 610,575	USD 151.58	USD 143.53
2025-11-25 (Tuesday)	66,527	USD 9,548,620	USD 9,548,620	825	USD 268,212	USD 143.53	USD 141.25
2025-11-24 (Monday)	65,702	USD 9,280,408	USD 9,280,408	165	USD -14,705	USD 141.25	USD 141.83
2025-11-21 (Friday)	65,537	USD 9,295,113	USD 9,295,113	0	USD 186,781	USD 141.83	USD 138.98
2025-11-20 (Thursday)	65,537	USD 9,108,332	USD 9,108,332	-660	USD -30,826	USD 138.98	USD 138.06
2025-11-19 (Wednesday)	66,197	USD 9,139,158	USD 9,139,158	165	USD -14,858	USD 138.06	USD 138.63
2025-11-18 (Tuesday)	66,032	USD 9,154,016	USD 9,154,016	990	USD -183,414	USD 138.63	USD 143.56
2025-11-17 (Monday)	65,042	USD 9,337,430	USD 9,337,430	330	USD -36,750	USD 143.56	USD 144.86

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of NBIX by Blackrock for IE00BDZVHG35

Show aggregate share trades of NBIX

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-12-02 BUY 2,475 153.790 150.855 151.148 USD 374,093 125.91
2025-11-28 BUY 165 153.700 150.410 150.739 USD 24,872 125.66
2025-11-26 BUY 495 153.540 146.000 146.754 USD 72,643 125.40
2025-11-26 BUY 495 153.540 146.000 146.754 USD 72,643 125.40
2025-11-25 BUY 825 144.750 140.667 141.075 USD 116,387 125.31
2025-11-24 BUY 165 143.505 139.270 139.694 USD 23,049 125.23
2025-11-20 SELL -660 138.980* 125.08 Profit of 82,553 on sale
2025-11-19 BUY 165 138.060* 125.02
2025-11-18 BUY 990 145.080 138.430 139.095 USD 137,704 124.95
2025-11-17 BUY 330 145.905 142.440 142.787 USD 47,120 124.85
2025-11-14 BUY 165 146.375 142.990 143.329 USD 23,649 124.75
2025-11-12 BUY 165 148.035 145.410 145.673 USD 24,036 124.53
2025-11-10 BUY 164 154.100 146.020 146.828 USD 24,080 124.28
2025-11-06 BUY 164 155.640 152.860 153.138 USD 25,115 123.97
2025-11-04 BUY 165 143.870 140.820 141.125 USD 23,286 123.71
2025-10-30 BUY 825 140.190 136.510 136.878 USD 112,924 123.43
2025-10-29 BUY 575 138.020 144.240 143.618 USD 82,580 123.35
2025-10-22 SELL -660 141.470 143.690 143.468 USD -94,689 122.74 Loss of -13,684 on sale
2025-10-20 BUY 330 141.330 142.590 142.464 USD 47,013 122.52
2025-10-17 BUY 824 140.090 140.470 140.432 USD 115,716 122.42
2025-10-15 BUY 1,312 137.730 139.460 139.287 USD 182,745 122.33
2025-10-03 BUY 1,141 137.030 137.800 137.723 USD 157,142 122.16
2025-10-02 BUY 163 136.740 137.630 137.541 USD 22,419 122.07
2025-09-30 BUY 326 140.380 141.690 141.559 USD 46,148 121.87
2025-09-26 BUY 326 142.000 142.080 142.072 USD 46,315 121.64
2025-09-25 BUY 326 140.890 145.610 145.138 USD 47,315 121.53
2025-09-18 BUY 170 145.660 146.030 145.993 USD 24,819 121.38
2025-09-17 BUY 513 142.730 143.390 143.324 USD 73,525 121.25
2025-09-11 SELL -171 143.600 143.820 143.798 USD -24,589 120.74 Loss of -3,943 on sale
2025-09-10 BUY 342 141.250 145.160 144.769 USD 49,511 120.61
2025-07-17 SELL -342 134.110 135.700 135.541 USD -46,355 120.23 Loss of -5,238 on sale
2025-07-16 BUY 594 133.480 134.250 134.173 USD 79,699 120.14
2025-07-11 SELL -1,352 133.460 135.000 134.846 USD -182,312 119.88 Loss of -20,236 on sale
2025-07-02 BUY 9,295 129.400 130.420 130.318 USD 1,211,306 119.56
2025-06-25 BUY 338 127.780 128.610 128.527 USD 43,442 119.36
2025-06-20 BUY 1,084 126.550 128.380 128.197 USD 138,966 119.20
2025-06-11 BUY 330 124.170 125.510 125.376 USD 41,374 118.88
2025-06-10 BUY 330 124.770 127.510 127.236 USD 41,988 118.83
2025-06-04 SELL -165 124.520 125.990 125.843 USD -20,764 118.64 Loss of -1,189 on sale
2025-04-23 BUY 165 103.220 106.200 105.902 USD 17,474 119.22
2025-04-10 SELL -1,320 90.720 94.250 93.897 USD -123,944 121.41 Profit of 36,319 on sale
2025-04-08 SELL -165 87.540 96.000 95.154 USD -15,700 122.10 Profit of 4,446 on sale
2025-04-07 SELL -165 93.250 96.440 96.121 USD -15,860 122.44 Profit of 4,342 on sale
2025-04-04 SELL -825 95.650 100.520 100.033 USD -82,527 122.75 Profit of 18,743 on sale
2025-04-01 BUY 1,433 107.000 110.890 110.501 USD 158,348 123.12
2025-03-31 SELL -489 110.600 112.600 112.400 USD -54,964 123.27 Profit of 5,314 on sale
2025-03-21 BUY 1,238 111.920 112.530 112.469 USD 139,237 123.98
2025-03-14 SELL -2,544 110.750 111.270 111.218 USD -282,939 124.93 Profit of 34,894 on sale
2025-03-07 SELL -318 113.040 115.000 114.804 USD -36,508 126.08 Profit of 3,585 on sale
2025-03-04 SELL -159 113.110 114.390 114.262 USD -18,168 126.69 Profit of 1,976 on sale
2025-02-25 BUY 318 115.900 120.000 119.590 USD 38,030 127.54
2025-02-19 SELL -159 114.260 114.930 114.863 USD -18,263 128.28 Profit of 2,133 on sale
2025-02-13 BUY 477 116.870 118.610 118.436 USD 56,494 129.33
2025-02-12 BUY 159 117.180 118.010 117.927 USD 18,750 129.57
2025-02-11 BUY 636 116.850 116.940 116.931 USD 74,368 129.84
2025-01-02 BUY 175 137.860 139.470 139.309 USD 24,379 123.46
2024-12-30 SELL -5,480 137.060 138.650 138.491 USD -758,931 123.05 Loss of -84,613 on sale
2024-11-18 SELL -2,595 117.620 118.320 118.250 USD -306,859 120.21 Profit of 5,080 on sale
2024-11-08 SELL -173 125.740 126.280 126.226 USD -21,837 119.33 Loss of -1,194 on sale
2024-10-21 SELL -173 116.570 117.890 117.758 USD -20,372 0.00 Loss of -20,372 on sale
Market high and low price is on the date.

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-12-02	BUY	2,475	153.790	150.855	151.148	USD 374,093	125.91
2025-11-28	BUY	165	153.700	150.410	150.739	USD 24,872	125.66
2025-11-26	BUY	495	153.540	146.000	146.754	USD 72,643	125.40
2025-11-26	BUY	495	153.540	146.000	146.754	USD 72,643	125.40
2025-11-25	BUY	825	144.750	140.667	141.075	USD 116,387	125.31
2025-11-24	BUY	165	143.505	139.270	139.694	USD 23,049	125.23
2025-11-20	SELL	-660			138.980*		125.08 Profit of 82,553 on sale
2025-11-19	BUY	165			138.060*		125.02
2025-11-18	BUY	990	145.080	138.430	139.095	USD 137,704	124.95
2025-11-17	BUY	330	145.905	142.440	142.787	USD 47,120	124.85
2025-11-14	BUY	165	146.375	142.990	143.329	USD 23,649	124.75
2025-11-12	BUY	165	148.035	145.410	145.673	USD 24,036	124.53
2025-11-10	BUY	164	154.100	146.020	146.828	USD 24,080	124.28
2025-11-06	BUY	164	155.640	152.860	153.138	USD 25,115	123.97
2025-11-04	BUY	165	143.870	140.820	141.125	USD 23,286	123.71
2025-10-30	BUY	825	140.190	136.510	136.878	USD 112,924	123.43
2025-10-29	BUY	575	138.020	144.240	143.618	USD 82,580	123.35
2025-10-22	SELL	-660	141.470	143.690	143.468	USD -94,689	122.74 Loss of -13,684 on sale
2025-10-20	BUY	330	141.330	142.590	142.464	USD 47,013	122.52
2025-10-17	BUY	824	140.090	140.470	140.432	USD 115,716	122.42
2025-10-15	BUY	1,312	137.730	139.460	139.287	USD 182,745	122.33
2025-10-03	BUY	1,141	137.030	137.800	137.723	USD 157,142	122.16
2025-10-02	BUY	163	136.740	137.630	137.541	USD 22,419	122.07
2025-09-30	BUY	326	140.380	141.690	141.559	USD 46,148	121.87
2025-09-26	BUY	326	142.000	142.080	142.072	USD 46,315	121.64
2025-09-25	BUY	326	140.890	145.610	145.138	USD 47,315	121.53
2025-09-18	BUY	170	145.660	146.030	145.993	USD 24,819	121.38
2025-09-17	BUY	513	142.730	143.390	143.324	USD 73,525	121.25
2025-09-11	SELL	-171	143.600	143.820	143.798	USD -24,589	120.74 Loss of -3,943 on sale
2025-09-10	BUY	342	141.250	145.160	144.769	USD 49,511	120.61
2025-07-17	SELL	-342	134.110	135.700	135.541	USD -46,355	120.23 Loss of -5,238 on sale
2025-07-16	BUY	594	133.480	134.250	134.173	USD 79,699	120.14
2025-07-11	SELL	-1,352	133.460	135.000	134.846	USD -182,312	119.88 Loss of -20,236 on sale
2025-07-02	BUY	9,295	129.400	130.420	130.318	USD 1,211,306	119.56
2025-06-25	BUY	338	127.780	128.610	128.527	USD 43,442	119.36
2025-06-20	BUY	1,084	126.550	128.380	128.197	USD 138,966	119.20
2025-06-11	BUY	330	124.170	125.510	125.376	USD 41,374	118.88
2025-06-10	BUY	330	124.770	127.510	127.236	USD 41,988	118.83
2025-06-04	SELL	-165	124.520	125.990	125.843	USD -20,764	118.64 Loss of -1,189 on sale
2025-04-23	BUY	165	103.220	106.200	105.902	USD 17,474	119.22
2025-04-10	SELL	-1,320	90.720	94.250	93.897	USD -123,944	121.41 Profit of 36,319 on sale
2025-04-08	SELL	-165	87.540	96.000	95.154	USD -15,700	122.10 Profit of 4,446 on sale
2025-04-07	SELL	-165	93.250	96.440	96.121	USD -15,860	122.44 Profit of 4,342 on sale
2025-04-04	SELL	-825	95.650	100.520	100.033	USD -82,527	122.75 Profit of 18,743 on sale
2025-04-01	BUY	1,433	107.000	110.890	110.501	USD 158,348	123.12
2025-03-31	SELL	-489	110.600	112.600	112.400	USD -54,964	123.27 Profit of 5,314 on sale
2025-03-21	BUY	1,238	111.920	112.530	112.469	USD 139,237	123.98
2025-03-14	SELL	-2,544	110.750	111.270	111.218	USD -282,939	124.93 Profit of 34,894 on sale
2025-03-07	SELL	-318	113.040	115.000	114.804	USD -36,508	126.08 Profit of 3,585 on sale
2025-03-04	SELL	-159	113.110	114.390	114.262	USD -18,168	126.69 Profit of 1,976 on sale
2025-02-25	BUY	318	115.900	120.000	119.590	USD 38,030	127.54
2025-02-19	SELL	-159	114.260	114.930	114.863	USD -18,263	128.28 Profit of 2,133 on sale
2025-02-13	BUY	477	116.870	118.610	118.436	USD 56,494	129.33
2025-02-12	BUY	159	117.180	118.010	117.927	USD 18,750	129.57
2025-02-11	BUY	636	116.850	116.940	116.931	USD 74,368	129.84
2025-01-02	BUY	175	137.860	139.470	139.309	USD 24,379	123.46
2024-12-30	SELL	-5,480	137.060	138.650	138.491	USD -758,931	123.05 Loss of -84,613 on sale
2024-11-18	SELL	-2,595	117.620	118.320	118.250	USD -306,859	120.21 Profit of 5,080 on sale
2024-11-08	SELL	-173	125.740	126.280	126.226	USD -21,837	119.33 Loss of -1,194 on sale
2024-10-21	SELL	-173	116.570	117.890	117.758	USD -20,372	0.00 Loss of -20,372 on sale

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of NBIX

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	138,304	0	280,714	49.3%
2025-09-18	207,776	44,506	326,194	63.7%
2025-09-17	106,323	343	194,597	54.6%
2025-09-16	97,811	19,146	256,980	38.1%
2025-09-15	73,363	0	197,457	37.2%
2025-09-12	71,817	1,305	193,968	37.0%
2025-09-11	87,204	0	250,369	34.8%
2025-09-10	117,099	0	288,605	40.6%
2025-09-09	123,379	1,879	226,941	54.4%
2025-09-08	213,669	1,667	350,787	60.9%
2025-09-05	269,882	8,988	447,930	60.3%
2025-09-04	193,322	481	275,129	70.3%
2025-09-03	210,597	108	556,905	37.8%
2025-09-02	183,319	15,512	318,150	57.6%
2025-08-29	101,061	7,590	154,079	65.6%
2025-08-28	127,383	487	193,561	65.8%
2025-08-27	137,454	1,818	217,033	63.3%
2025-08-26	170,022	3,558	291,096	58.4%
2025-08-25	124,153	3,639	195,476	63.5%
2025-08-22	126,629	10,885	196,288	64.5%
2025-08-21	119,245	1,265	200,990	59.3%
2025-08-20	135,138	4,637	230,010	58.8%
2025-08-19	186,010	535	287,330	64.7%
2025-08-18	162,038	7,351	232,609	69.7%
2025-08-15	140,024	100	220,199	63.6%
2025-08-14	290,907	253	363,139	80.1%
2025-08-13	356,404	8,730	466,191	76.5%
2025-08-12	303,975	4,067	434,641	69.9%
2025-08-11	279,191	5,617	413,027	67.6%
2025-08-08	338,385	0	490,220	69.0%
2025-08-07	341,719	2	486,060	70.3%
2025-08-06	162,494	52	290,741	55.9%
2025-08-05	127,812	122	285,401	44.8%
2025-08-04	184,650	798	554,601	33.3%
2025-08-01	384,652	274	613,137	62.7%
2025-07-31	795,027	2	1,403,519	56.6%
2025-07-30	277,359	199	566,942	48.9%
2025-07-29	235,483	1,232	479,504	49.1%
2025-07-28	128,796	1,272	304,763	42.3%
2025-07-25	164,959	0	533,682	30.9%
2025-07-24	143,137	442	360,991	39.7%
2025-07-23	127,087	250	336,567	37.8%
2025-07-22	110,378	700	199,614	55.3%
2025-07-21	94,768	91	171,481	55.3%
2025-07-18	136,185	216	238,836	57.0%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Note: All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.

Stock Name / Fund	iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer	Blackrock
ETF Ticker	BTEE(USD) LSE
ETF Ticker	BTEE.L(GBP) LSE